-
公开(公告)号：US20240052054A1
公开(公告)日：2024-02-15
申请号：US18483174
申请日：2023-10-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike HUTT , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER , Martin HOFMANN , Gabriele PSZOLLA , Sara YOUSEF , Claudia WAGNER , Frank SCHWOEBEL , Heiko SCHUSTER
IPC: C07K16/30 , C07K14/725 , A61P35/00
CPC classification number: C07K16/30 , C07K14/7051 , A61P35/00 , C07K2317/32 , C07K2317/24 , C07K2317/622 , C07K2317/567 , C07K2317/92 , C07K2317/55 , C07K2317/565
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20230190808A1
公开(公告)日：2023-06-22
申请号：US17938577
申请日：2022-10-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Jens FRITSCHE , Oliver SCHOOR , Frank SCHWOEBEL , Lena Katharina FREUDENMANN
IPC: A61K35/17 , C07K14/725 , C12N5/0783 , C12N5/10
CPC classification number: A61K35/17 , C07K14/7051 , C12N5/0638 , C12N5/10
Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
-
公开(公告)号：US20210032361A1
公开(公告)日：2021-02-04
申请号：US16943779
申请日：2020-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike HUTT , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER , Martin HOFMANN , Gabriele PSZOLLA , Sara YOUSEF , Claudia WAGNER , Frank SCHWOEBEL , Heiko SCHUSTER
IPC: C07K16/30 , C07K14/725 , A61P35/00
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20240092933A1
公开(公告)日：2024-03-21
申请号：US18511308
申请日：2023-11-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Gabriele PSZOLLA , Martin HOFMANN , Meike HUTT , Sebastian BUNK , Felix UNVERDORBEN , Frank SCHWOEBEL , Dominik MAURER , Maike JAWORSKI , Claudia WAGNER , Florian SCHWOERER , Heiko SCHUSTER
CPC classification number: C07K16/30 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20240075130A1
公开(公告)日：2024-03-07
申请号：US18505361
申请日：2023-11-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Jens FRITSCHE , Oliver SCHOOR , Frank SCHWOEBEL , Lena Katharina FREUDENMANN
IPC: A61K39/385 , A61K35/17 , A61K38/17 , A61K38/20 , A61P11/00 , A61P35/04 , A61P37/04 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N5/10 , G01N33/574
CPC classification number: A61K39/385 , A61K35/17 , A61K38/1774 , A61K38/20 , A61K38/2046 , A61K38/2086 , A61P11/00 , A61P35/04 , A61P37/04 , C07K14/7051 , C07K16/2809 , C12N5/0638 , C12N5/10 , G01N33/57492 , A61K2039/53
Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
-
Patent Agency Ranking
公开(公告)号：US20230190807A1
公开(公告)日：2023-06-22
申请号：US17938317
申请日：2022-10-05
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Jens FRITSCHE , Oliver SCHOOR , Frank SCHWOEBEL , Lena Katharina FREUDENMANN
CPC classification number: A61K35/17 , A61K38/1774 , A61P35/04 , C07K16/2809 , C07K2317/55 , C07K2317/626 , C07K2317/73
Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
-
公开(公告)号：US20230181729A1
公开(公告)日：2023-06-15
申请号：US17938505
申请日：2022-10-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Jens FRITSCHE , Oliver SCHOOR , Frank SCHWOEBEL , Lena Katharina FREUDENMANN
IPC: A61K39/385 , A61P35/04
CPC classification number: A61K39/385 , A61P35/04 , A61K2039/53
Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
-
公开(公告)号：US20240117068A1
公开(公告)日：2024-04-11
申请号：US18538242
申请日：2023-12-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike HUTT , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER , Martin HOFMANN , Gabriele PSZOLLA , Sara YOUSEF , Claudia WAGNER , Frank SCHWOEBEL , Heiko SCHUSTER
IPC: C07K16/30 , A61P35/00 , C07K14/725
CPC classification number: C07K16/30 , A61P35/00 , C07K14/7051 , C07K2317/24 , C07K2317/32 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/92
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20230357428A1
公开(公告)日：2023-11-09
申请号：US18301545
申请日：2023-04-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Gabriele PSZOLLA , Martin HOFMANN , Meike HUTT , Sebastian BUNK , Felix UNVERDORBEN , Frank SCHWOEBEL , Dominik MAURER , Maike JAWORSKI , Claudia WAGNER , Florian SCHWOERER , Heiko SCHUSTER
CPC classification number: C07K16/30 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20230190805A1
公开(公告)日：2023-06-22
申请号：US17938311
申请日：2022-10-05
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Jens FRITSCHE , Oliver SCHOOR , Frank SCHWOEBEL , Lena Katharina FREUDENMANN
IPC: A61K35/17 , G01N33/574 , C07K14/725 , A61P35/04 , A61P11/00
CPC classification number: A61K35/17 , G01N33/57492 , C07K14/7051 , A61P35/04 , A61P11/00 , C07K2317/565 , C07K2317/626 , C07K2317/622 , C07K2317/55
Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.015 seconds)
